Snapshot · Gilead Sciences, Inc. (GILD)

Data as of 2026-08-30T11:28:33.298Z

Fundamentals check

Market cap

$180.9B

P/E (TTM)

-56.0

Gross margin

79.6%

Net margin

-10.6%

ROE

-16.3%

R&D / revenue

19.9%

Dividend yield

2.2%

FCF yield

7.3%

Latest dividend: $0.82/share (ex-date 2026-09-15, quarterly)

Summary

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

How it makes money

Revenue mix, latest fiscal year

• Products, Other HIV79.7%
• Cell Therapy Products, Total Cell Therapy Product Sales8.4%
• Trodelvy5.4%
• Veklury3.5%
• Other Products, Total Other product sales3.1%

Recent Events

• 2026-08-27T17:47:00.000Zpositive

  U.S. FDA Approves Gilead's Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens

  恰逢FDA批准新一日一次用药方案，可能有助于简化治疗并拓展患者人群，相关产品线潜在增长。

  Source: businesswire.com

• 2026-08-18T00:00:00.000Zpositive

  Price move: GILD rose 3.3%

  GILD 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-04T16:01:00.000Zpositive

  Gilead Sciences Announces Second Quarter 2026 Financial Results

  可能与收入同比增长10%及 HIV 组合驱动的基础业务改善相关，恰逢财报披露，市场对2026年收入前景乐观。

  Source: businesswire.com

• 2026-08-04T00:00:00.000Zpositive

  Price move: GILD rose 3.1%

  GILD 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-03T13:04:42.000Zneutral

  California's highest court rules for Gilead in 'duty to innovate' case

  恰逢司法裁决有利于Gilead，但不构成直接因果关系，可能与公司在创新承诺方面的形象相关。

  Source: reuters.com

• 2026-07-16T00:00:00.000Zpositive

  Price move: GILD rose 3.5%

  GILD 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-07-07T00:00:00.000Zpositive

  Price move: GILD rose 5.2%

  GILD 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-06-26T00:00:00.000Zpositive

  Price move: GILD rose 3.3%

  GILD 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-06-11T00:00:00.000Zpositive

  Price move: GILD rose 3.6%

  GILD 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

Analyst view

Avg price target $141.44 from 9 analysts (last quarter)

Insider & Congress activity

Open-market trades only; grants and exercises excluded

• 2026-08-26SellWELTERS ANTHONY(director)6,880 shares
• 2026-08-26SellWELTERS ANTHONY(director)4,600 shares
• 2026-08-26SellWELTERS ANTHONY(director)3,118 shares
• 2026-08-26SellWELTERS ANTHONY(director)3,402 shares
• 2026-08-20SellBluestone Jeffrey(director)1,658 shares

订阅每日简报

每个交易日开盘/收盘后，中文市场简报直达邮箱。免费，随时退订。

本内容仅为信息整理，不构成任何投资建议。